Overview
- Private providers and online pharmacies in the UK report very large waiting lists and first‑day order spikes for the newly approved Wegovy oral tablet, with some firms citing tens of thousands of people signed up.
- Clinical trial data show the oral semaglutide pill produces meaningful weight loss at an average of about 17 percent and uses a daily, stepped dosing schedule that rises to a 25mg maintenance dose.
- For now the pill is expected to be sold privately rather than on the NHS, with provisional price estimates around £99 a month from some pharmacists and the first private prescriptions likely to start in the summer.
- Experts warn the tablet requires far more active ingredient than injections—quoted as roughly 100 times per dose—raising a clear risk that demand could strain manufacturing even as Novo Nordisk says it is confident supply will be sufficient.
- If demand holds, the oral option could draw older adults and more men who avoided injections and widen the pool of patients using GLP‑1 drugs, repeating earlier dynamics that caused shortages of injectable treatments and will shape access and rollout.